| Assessment Status | Rapid Review Complete |
| HTA ID | 20012 |
| Drug | Infliximab |
| Brand | Remsima SC® |
| Indication | In combination with methotrexate, is indicated in rheumatoid arthritis for the reduction of signs and symptoms as well as the improvement in physical function in: adult patients with active disease when the response to disease modifying antirheumatic drugs (DMARDs), including methotrexate, has been inadequate; adult patients with severe, active and progressive disease not previously treated with methotrexate or other DMARDs. |
| Assessment Process | |
| Rapid review commissioned | 04/03/2020 |
| Rapid review completed | 24/03/2020 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that infliximab SC not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.
